Oryzon anuncia el inicio de su Fase I con su molécula para el Alzheimer ORY-2001

Oryzon Genomics, compañía biofarmacéutica en fase clínica, centrada en epigenética para el desarrollo de terapias en oncología ...

(English) Oryzon Announces First Subject Dosed in Phase I Healthy Volunteer Study Evaluating Oral Epigenetic drug ORY-2001 for Alzheimer’s Disease

Oryzon Genomics (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies ...

(English) Oryzon to Present at the Neuroscience R&D Technologies Conference

Oryzon Genomics announced today that Dr. Tamara Maes, Oryzon’s Chief Scientific Officer, will present at the Neuroscience ...